ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Comorbidity"

  • Abstract Number: 1542 • ACR Convergence 2023

    The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study

    Zachary Wallace1, Xiaoqing Fu2, Shruthi Srivatsan2, Zachary Williams2, Claire Cook2, Jennifer Hanberg2, John Stone3, Hyon K. Choi4 and Yuqing Zhang5, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA, 5Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA

    Background/Purpose: With improvements in the risks of relapse and mortality in ANCA-associated vasculitis (AAV), a better understanding of disease- and treatment-related complications is necessary to…
  • Abstract Number: 0723 • ACR Convergence 2023

    Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

    Xiaoyue Deng1, Junyan Qian1, Ranran Wang2, JIULIANG ZHAO3, Qian Wang4, Tianyi Yuan2, MENGTAO LI1 and Xiaofeng Zeng5, 1Peking Union Medical College Hospital, Beijing, China, 2Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Beijing Union Medical College Hospital, Beijing, China, 4Peking Union Medical College, Beijing, China, 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a serious complication in SLE patients, with rapid progression and poor prognosis. In China, approximately 3% of the over…
  • Abstract Number: 1631 • ACR Convergence 2023

    Comparison of Peripheral Biomarker Profiles Across Unique Multimorbidity Patterns in Rheumatoid Arthritis

    Chloe Peyton1, Tate Johnson1, Joshua Baker2, Yangyuna Yang1, Punyasha Roul1, Michael Duryee1, Jill Poole1, Geoffrey Thiele1, Ted R Mikuls3 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) predisposes affected individuals to develop multiple chronic conditions (i.e., multimorbidity). Mechanisms underlying multimorbidity onset in RA are incompletely understood, particularly for…
  • Abstract Number: 0739 • ACR Convergence 2023

    Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis

    Sali Merjanah1, Devin Driscoll2, Christine Peloquin3, Jean liew3 and Maureen Dubreuil4, 1Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 2Boston University/Boston Medical Center, Boston, MA, 3Boston University, Boston, MA, 4Department of Rheumatology, Boston University School of Medicine, Milton, MA

    Background/Purpose: Individuals with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) have increased cardiovascular risk compared to the general population, which is partly explained by systemic…
  • Abstract Number: 1632 • ACR Convergence 2023

    Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care

    Martin Schaefer1, Yvette Meissner1, Bernhard Manger2, Sylvia Berger3, Karin Rockwitz4, Anne Regierer5 and Anja Strangfeld1, 1German Rheumatism Research Center, Berlin, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Rheumatologist, Naunhof, Germany, 4Rheumatologist, Goslar, Germany, 5Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany

    Background/Purpose: In 2021, the European and US-American regulatory agencies EMA and FDA issued warnings about malignancy risk associated with the Janus kinase inhibitor (JAKi) tofacitinib…
  • Abstract Number: 0869 • ACR Convergence 2023

    Clinical Impact of PTEN as a Marker for Diabetes-Associated Osteoarthritis

    Irene Lorenzo Gomez1, Uxía nogueira Recalde2, Christian García Domínguez1, Natividad Oreiro Villar3, Jose Antonio Pinto Tasende3, Mohit Kapoor4, Francisco J. Blanco3 and Beatriz Carames1, 1Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (iNIBIC), A Coruña, Spain, 2Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomedica de A Coruña (iNIBIC), A Coruña, Spain, 3Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 4Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: Defects in homeostatic mechanisms, such as autophagy, contribute to joint aging and Osteoarthritis (OA) and precede joint damage (1). OA is a complex and…
  • Abstract Number: 1855 • ACR Convergence 2023

    Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia

    Gary Macfarlane1, Roxanne Cooksey2, Ernest Choy3 and Rosemary Hollick4, 1Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, 2Cardiff University, Cardiff, United Kingdom, 3Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, 4University of Aberdeen, Aberdeen, United Kingdom

    Background/Purpose: A large body of evidence has informed, internationally, management recommendations for people with fibromyalgia. However there are very few studies which have examined how…
  • Abstract Number: 0124 • ACR Convergence 2022

    Evaluation of Comorbidity Burden and Its Effect on Lung Disease Progression and Mortality in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features

    Elena Joerns1, Michelle Ghebranious1, Traci Adams1 and Una Makris2, 1UT Southwestern, Dallas, TX, 2UT Southwestern Medical Center and Dallas VA, Dallas, TX

    Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) which manifests with interstitial pneumonia and features of autoimmunity, yet…
  • Abstract Number: 1390 • ACR Convergence 2022

    Distinct Patterns of Multimorbidity Are Associated with Longitudinal Disease Activity and Functional Status in a Multicenter, Prospective Rheumatoid Arthritis Cohort

    Sarah Dutt1, Punyasha Roul2, Yangyuna Yang3, Kaleb Michaud3, Brian Sauer4, Grant Cannon5, Joshua Baker6, Jeffrey Curtis7, Ted Mikuls8 and Bryant England3, 1University of Nebraska Medical Center, Omaha, 2UNMC, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE, 4Salt Lake City VA/University of Utah, Salt Lake City, UT, 5Salt Lake City VA, Salt Lake city, 6University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 7Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 8Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) predisposes to the development of other chronic conditions such as osteoporosis, cardiovascular disease, and lung disease. Previously, we used unsupervised machine…
  • Abstract Number: 1953 • ACR Convergence 2022

    Mortality in Rheumatoid Arthritis: Changing Causes and Predictive Factors. Study of a Cohort Followed Prospectively

    Cristina Corrales1, Fabricio Benavides Villanueva1, Ivan Ferraz Amaro2, Nuria Vegas Revenga3, Virgi Portilla4, Ricardo Blanco5, Miguel Ángel González-Gay6 and Alfonso Corrales4, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 3Hospital Galdakao- Usansolo, Galdakao, Spain, 4Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 6Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Patients with Rheumatoid Arthritis (RA) present an increased risk of mortality. In the last decades, mortality rates tended to decrease but cardiovascular (CV) events…
  • Abstract Number: 0189 • ACR Convergence 2022

    Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study

    Alexis Ogdie1, April Armstrong2, Barbra Bohannan3, Sicily Mburu4, Laura Coates5, Elena Kornyeyeva6, Susan Frade6, Silvia Fernandez Barrio7 and Matthias Augustin8, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Keck School of Medicine of USC, Dermatology, Los Angeles, CA, 3Psoriasisförbundet, Stockholm, Sweden, 4IFPA, Stockholm, Sweden, 5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 6Novartis Pharma AG, Basel, Switzerland, 7Asociación Para El Enfermo De Psoriasis, Buenos Aires, Argentina, 8University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Background/Purpose: Psoriatic arthritis (PsA) is a common clinical feature in patients (pts) with psoriasis (PsO); up to one third of PsO pts will develop PsA…
  • Abstract Number: 1408 • ACR Convergence 2022

    In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study

    Reinder Raadsen1, Rabia Agca2, Maarten Boers3, Vokko van Halm2, Mike Peters4, Yvo Smulders2, Joline Beulens2, Marieke Blom2, Coen Stehouwer5, Alexandre Voskuyl2, Willem Lems6 and Michael Nurmohamed7, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands, 3Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 4Amsterdam UMC; UMC Utrecht, Amsterdam, Netherlands, 5MUmc, Amsterdam, Netherlands, 6Amsterdam University Medical Centers, Amsterdam, Netherlands, 7Amsterdam University Medical Center, Kortenhoef, Netherlands

    Background/Purpose: We have documented that patients with rheumatoid arthritis (RA) are at increased risk to develop cardiovascular disease (CVD) compared to the general population, even…
  • Abstract Number: 1964 • ACR Convergence 2022

    Systematic Screening of Multimorbidities Results in an Increased Intake of Comorbidity Preventive Medications and a Decreased Hospitalization Rate

    Claire DAIEN1, Vera Georgescu2, Guillaume Decarriere3, Jenica Pastor3, Gaël Mouterde4, Cédric Lukas5, Grégoire Mercier3 and Jacques Morel6, 1University Hospital, Saint-Gély-du-Fesc, France, 2Unité de Recherche Médico-économique, CHU de Montpellier et Université de Montpellier, Montpellier, France, 3CHU Montpellier, Montpellier, France, 4Lapeyronie Hospital, Montpellier, France, 5University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, 6University and CHU Montpellier, Montpellier, France

    Background/Purpose: A systematic screening of multimorbidities is performed since 2014 at the Montpellier University Hospital in patients with chronic inflammatory rheumatic diseases (IRD). The objective…
  • Abstract Number: 0246 • ACR Convergence 2022

    Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Prognosis

    Cynthia Crowson1, Tina Gunderson2, John Davis2, Elena Myasoedova2, Vanessa Kronzer2, Caitrin Coffey2, Bradly Kimbrough3 and Elizabeth Atkinson2, 1Mayo Clinic, Eyota, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic Rochester, Rochester, MN

    Background/Purpose: Comorbidities are common in patients with rheumatoid arthritis (RA), but there is little information regarding the occurrence of distinct comorbidity patterns in patients with…
  • Abstract Number: 1506 • ACR Convergence 2022

    Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study

    Paras Karmacharya1, Rikesh Chakradhar2, Alexis Ogdie3, John Davis4, Tina Gunderson4, Cassondra Hulshizer4, Kerry Wright4, Megha M. Tollefson5, Ali Duarte-Garcia4, Delamo Bekele4, Hilal Maradit Kremers4, Floranne Ernste4 and Cynthia Crowson6, 1Vanderbilt University, Nashville, TN, 2St. Christopher's Hospital, Philadelphia, 3Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4Mayo Clinic, Rochester, MN, 5Mayo Clinic, Rochester, 6Mayo Clinic, Eyota, MN

    Background/Purpose: Psoriasis is a systemic inflammatory disorder associated with cardiometabolic and other comorbidities. Psoriasis frequently precedes development of psoriatic arthritis (PsA), and comorbidities in psoriasis…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology